APZORECOPETIFIE 03 AUG 2006

Attorney Docket No.: 10582.204-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Duffner et al.

Confirmation No: To be assigned

Serial No.: TBA

Group Art Unit: To be assigned

Filed: August 03, 2006

For: Xylanase

Examiner: To be assigned

·

INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)

Mail Stop Amendment Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

This IDS is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted.

Date: August 03, 2006

Jasop I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110

(212)840-0097

MP20 Rec'd PCT/PTO 03 AUG 2006

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

10582,204-US

12/17/2009

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless to control service with the Commerce of th

Attorney Docket Number

2

Sheet

Examiner

Signature

of

/Hamid Badr/

	U.S PATENT DOCUMENTS										
Examiner Initials	Cite No. 1	Document Number Number – Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear						
/HRB/		US 20040028773	02-12-2004	Sturkenboon et al							
	1==										
	-										
	+										
	1										
	+	 									

		FOREIGN F	ATENT DOCU	MENTS		
Examiner Initials	Cite No. 1	Foreign Patent Document Country Code 3 – Number 4 – Kind Code 5 (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pegas, Columns, Lines, Where Ralevant Passages or Relevant Figures Appear	т•
/HRR/		WO 03/106654	12-24-2003	Versa Corp		
		WO 00/39289	07-06-2000	Danisco		
\sqrt{I}		WO 96/32472	10-17-1996	Novo Nordisk		
V		WO 95/23515	09-08-1995	Novo Nordisk		
	-					
	-					
						_
			_			

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to epplicant.

Date

Considered

*Applicant's unique classion designation number (optional). *Bee Kinds Codes of USPTO Patent Documents at www.uspid.oog.com/MPP 901.04 *Enter Office that issued the number of the petent document. *White of document is the petent of the petent document. *White of document is the petent of the petent document. *White of document is the petent of the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents. **Specialists in by pilot as indicated on the document under WPO Standard ST 1.18 petents in by pilot as indicated on the document under WPO Standard ST 1.18 petents in by pilot as indicated on the document under WPO Standard ST 1.18 petents in by pilot as indicated on the document under WPO Standard ST 1.18 petents in by pi

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the encurs of lime you are required to complete this form should be sent to be offer information follow, U.S. Patient and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patients, Washington, DC 2018.

IAP20 Rec'd PCT/PTO 03 AUG 2006

PTC/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

12/17/2009

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERC
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known Application Number INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT First Named Inventor Duffner et al. Art Unit To be assigned (use as many sheets as necessary) **Examiner Name** To be assigned Sheet of 2 Attorney Docket Number 10582.204-US 2

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T 2
		EMBL-EBI, Accession # D32065, (1994)	
/HRB/			
/HRB/		EMBL-EBI, Accession # AF195421, (2000)	
/HRB/		Kubata et al, Bio Science Biotech, Biochemistry, Vol. 56, Part 9, pages 1463-1464 (1992)	
Examiner		(Hamid Badri Date 19/17/2000	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

/Hamid Radr/

Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the arount of time you are required to complete this form should be sent to the Chief Information Office, U.S. Patient and Trademark. Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patients, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.